Metformin Combats Obesity by Targeting FTO in an M6a-Ythdf2-dependent Manner

Xing Liao,Jiaqi Liu,Yushi Chen,Youhua Liu,Wei Chen,Botao Zeng,Yuxi Liu,Yaojun Luo,Chaoqun Huang,Guanqun Guo,Yizhen Wang,Xinxia Wang
DOI: https://doi.org/10.1080/1061186x.2022.2071906
2022-01-01
Journal of Drug Targeting
Abstract:Obesity has become a health threat and hard enough to deal with. Evidences show that metformin could inhibit adipogenesis and combat obesity, while its mechanisms remain to be elucidated more comprehensively. In this study, we found that administration of metformin could combat obesity of mice induced by high-fat diet (HFD), indicated by strikingly decreased body weight and weight of inguinal white adipose tissue (iWAT) and epidydimal white adipose tissue (eWAT) compared with the control group. Mechanically, we revealed that metformin could inhibit protein expression of FTO, leading to increased m(6)A methylation levels of cyclin D1 (Ccnd1) and cyclin dependent kinase 2 (Cdk2), two crucial regulators in cell cycle. Ccnd1 and Cdk2 with increased m(6)A levels were recognised by YTH m(6)A RNA binding protein 2 (YTHDF2), causing an YTHDF2-dependent decay and decreased protein expressions. In consequence, mitotic clonal expansion (MCE) process was blocked and adipogenesis was inhibited.
What problem does this paper attempt to address?